$COO

Cooper Companies (NASDAQ: COO) director buys shares outside preset trading plan

Cooper Companies director Walter M. Rosebrough Jr. bought 10,000 shares of common stock on September 11 and 14, 2026, at average prices of $54.11 and $54.29 per share. The purchases were made indirectly through a revocable trust and were not part of a preset trading plan.

Original reporting
Published Sep 15, 2026, 8:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 9:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$COO
Neutral
medium confidence
Mentioned
$COO
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$COONeutralLow
01

Why it matters

The disclosed purchase adds a small amount of insider confidence but is unlikely to affect price materially.

02

Market read

A modest insider purchase with limited immediate trading relevance.

03

What to watch

No 10b5‑1 plan and modest size reduce the significance of the trade.

Relevance 4/10Novelty 5/10Timing: post‑trade disclosure September 2026

Background

Cooper Companies (NASDAQ: COO) is a medical device and vision care firm; insider trades are regularly reported via Form 4 filings.

Company-level read

Ticker impact

$COONeutralMedium confidence
Context

Director Walter M. Rosebrough Jr. disclosed open‑market purchases of 10,000 shares at $54.11‑$54.29, totaling about $542k, not under a 10b5‑1 plan.

Expected impact

Potential minor upside pressure, unlikely to move the stock significantly.

Evidence & confidence

Purchase size is small relative to market cap and not part of a pre‑arranged plan, so market reaction is expected to be muted.

Market effects

Insider activity may be noted by healthcare investors but does not alter sector outlook.

Limited to US markets; no broader regional effect.

Minimal global relevance.

Counterpoint

The purchase could be a routine portfolio rebalancing rather than a bullish signal.

Key entities

  • Walter M. Rosebrough Jr.

    Cooper Companies board member and sole trustee of a revocable trust that made the purchases.

Related articles

$COOMedAI 8/10

A Failed Auction and a 15% Drop: Is Cooper Companies (COO) a Value Trap or a Bargain?

Cooper Companies (COO) ended its 9-month effort to sell CooperSurgical after bids undervalued the business, according to management. The stock dropped 15% to a 52-week low near $51 after a Q3 miss and cut outlook. The company's core contact lens business, CooperVision, posted flat organic revenue growth, contributing to the guidance cut. Management authorized a $1B share repurchase program, while Bank of America questioned the valuation. COO reported record Q3 free cash flow of $273M.

$COOMedAI 8/10

The Cooper Companies (COO) Faces Near-Term Pressure from Slowing Contact Lens Demand

The Cooper Companies (COO) lowered its fiscal 2026 profit and revenue forecasts due to weaker-than-expected contact lens demand, with adjusted EPS now expected at $4.51–$4.55 and revenue at $4.23–$4.25 billion. Q3 revenue was $1.07 billion, missing estimates, though adjusted EPS beat at $1.15. The company cited U.S. channel inventory reductions as a key factor and decided to retain CooperSurgical.

$COOMedAI 8/10

Cooper Companies (COO) Bets on Fertility Growth Despite Weakness in CooperVision

Cooper Companies (COO) reported Q3 FY2026 revenue of $1.066B, up 1%, and adjusted EPS of $1.15, up 4%. The company spent $339.1M on share buybacks and has $1.5B remaining in repurchase capacity. Fertility segment growth and strong cash flow offset weakness in CooperVision, which saw flat organic growth and revenue declines in Americas and Asia Pacific. Gross margin improved to 67% on a GAAP basis, while adjusted operating margin rose 30 basis points to 26%.

$COOMed

Why Cooper, Freeport-McMoRan, and Baker Hughes Plunged

Cooper Companies (COO) fell 14.67% after reporting Q3 revenue of $1.07B and Q4 guidance below estimates. Freeport-McMoRan (FCX) dropped 6.59% due to White House uncertainty on copper tariffs. Baker Hughes (BKR) declined 6.66% despite raising its full-year revenue guidance to $28.5B-$30.3B.

$COOMedAI 8/10

COO Q2 Deep Dive: Inventory Actions and Strategic Review Shape Guidance

CooperCompanies reported Q2 revenue of $1.07B (flat YoY, 2.9% miss) and adjusted EPS of $1.15 (2.7% beat). Full-year guidance was lowered to $4.24B revenue and $4.53 EPS. The company reduced U.S. inventory and retained CooperSurgical after a strategic review. Management plans to invest in sales and R&D, aiming for future growth and improved margins.

$COOMedAI 8/10

Why is CooperCompanies Stock Down 15% Today?

CooperCompanies (COO) shares dropped 13.9% after Q3 earnings beat estimates but Q4 guidance fell short of expectations. The company also decided to retain CooperSurgical, removing a potential deal catalyst. U.S. distributor destocking is expected to continue impacting CooperVision's Q4 performance.